Home > Healthcare > Medical Devices > Therapeutic Devices > Diabetes Care Devices Market

Diabetes Care Devices Market Trends

Report ID: GMI3250
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Diabetes Care Devices Market Trends

The integration of smart technology into insulin delivery devices, such as insulin pens and pumps, has significantly transformed the landscape of diabetes management. This innovation not only enhances the convenience for individuals with diabetes but also improves the overall efficacy of treatment.

Smart insulin delivery devices allow for real-time monitoring of insulin usage and glucose levels. This data is often transmitted wirelessly to connected devices such as smartphones or dedicated apps.
Healthcare providers can remotely access this data, enabling them to closely monitor patients' glucose patterns, identify trends, and make informed adjustments to treatment plans without requiring frequent in-person visits.
Patients can actively engage in their diabetes management through user-friendly interfaces on connected devices. These interfaces often provide visual representations of glucose trends, medication adherence, and other relevant metrics.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

The global diabetes care devices industry was valued at around USD 46.1 billion in 2023 and is estimated to reach over USD 107.2 billion by 2032 due to the growing prevalence of diabetes across the world.

The blood glucose monitoring devices segment will record 9.9% CAGR during 2024-2032, attributed to the adoption of CGM systems for continuous and real-time monitoring of glucose levels to ensure optimal care to diabetes patients.

North America diabetes care devices industry accounted for USD 18.6 billion in 2023 and is predicted to witness substantial growth through 2032 due to the ongoing advancements in technology, including the integration of smart features, connectivity, and data-sharing capabilities in medical devices.

Abbott Laboratories, Arkray, Inc., Ascensia Diabetes Care Holding AG, B. Braun Melsungen AG, Becton Dickinson and Company, Bionime Corporation, DarioHealth Corp., Dexcom, Inc., Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche AG, Insulet Corporation, LifeScan, Inc., Medtronic plc, Nova Biomedical, Inc., Novo Nordisk A/S, Pendiq GmBH, Sanofi, Sinocare, Inc., Tandem Diabetes Care Inc., and Ypsomed AG.